Novo Holdings — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsBlackstone Life SciencesEight Roads VenturesF-Prime CapitalNYBC Ventures
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersHBM Healthcare InvestmentsT. Rowe PriceWellington Management
Kivu Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, using site-specific conjugation technology to create more stable and homogeneous cancer therapies with reduced off-tumor toxicity.
BiotechDeep TechHealthtech
Mohit Trikha(CEO)
Co-investorsBOMHealthCapM VenturesRed Tree VentureBioGeneration Ventures
Deep tech company; invested from Fund I in 2015
BiotechBozeman, US
Justin DuBois(Director)George Miljanich(Executive Officer)Stan Abel(Executive Officer, Director)
BoardWill Price(Director)inLowell Sears(Director)Joseph Zakrzewski(Director)
Co-investorsNext Frontier CapitalMission BiocapitalOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.